Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

d constipation (OIC).

Mickle continued, "The next clinical milestone for KP201 will be the completion of oral and intranasal abuse liability studies in the first quarter of 2014.  These studies will be important indicators of KP201's unique abuse-deterrent capabilities, which we believe are unlike any prescription opioid on the market or in development."

About KemPharm

KemPharm is abiopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the third quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

319-665-2575

info@kempharm.com

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020


SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Texas (PRWEB) , ... September 03, 2015 , ... ... suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not ... in late June 2015. Dr. McKenna treated Zack with precisely guided injections ...
(Date:9/3/2015)... PUNE, India , September 3, 2015 ... "Chromatography Instruments Market by System (LC (HPLC, UHPLC, Flash), ... (Reverse Phase Columns, Syringe Filters, Vials) - Analysis & ... Instruments Market is expected to reach around 9.223 Billion ... a CAGR of 5.5%. Browse 141 tables ...
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
Breaking Biology Technology:UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3
... SOPHIA ANTIPOLIS, France, February 26 NicOx,S.A. (NYSE ... for,full year 2008 and provided an overview of ... investigational,drug for the treatment of the signs and ... Michele Garufi, Chief Executive Officer of NicOx, ...
... National Research Council,s National Institute (NINT) for Nanotechnology have ... of plastic solar cells (hybrid organic solar cells). The ... goal of intense interest for many of the world,s ... shortage of the ultra-high purity silicon and other materials ...
... MDV3100 Consistently Demonstrates Anti-Tumor Activity Across Doses and Endpoints ... To Be Presented at ASCO,s 2009 Genitourinary Cancers Symposium ... with Dr. Howard Scher Today at 4:30 p.m. Eastern ... (Nasdaq: MDVN ) today announced the presentation ...
Cached Biology Technology:Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 2Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 3Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 4Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 5Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 6Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 7Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 8Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 9Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 10Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 11Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 12Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 13Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 14Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 15University of Alberta and NINT researchers make solar energy breakthrough 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 5
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... North and South Carolina have seen a steady increase in ... alone, swine production generates approximately a quarter of the state,s ... farms leads to the problem of proper animal waste disposal. ... animal waste in anaerobic lagoons. They are primarily used to ...
... In a Memorandum of Understanding signed today, the ... (EMBL) formalise their desire to maintain and further develop ... renewed and strengthened Memorandum of Understanding between the European ... confident that it will set the stage for even ...
... is seeking a new way to help those who ... this isn,t "The King,s Speech," the Academy Award-winning film ... a stammer. Instead, Alexander Leonessa ( http://www.me.vt.edu/people/faculty/leonessa.html ) wants ... and others who have suffered paralysis of the vocal ...
Cached Biology News:Environmental impact of animal waste 2Virginia Tech researcher seeks to use electrical stimulation to give voice to stroke patients 2Virginia Tech researcher seeks to use electrical stimulation to give voice to stroke patients 3
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
... consists of AmnioMAX-C100 Basal ... and AmnioMAX-C100 Supplement (Cat. ... complete with antibiotics and ... requires no further supplementation ...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... polyclonal to Parathyroid Hormone Receptor 2 ... applications). Antigen: ... amino acids 99-116 of Human Parathyroid ... Entrez Gene ID: 5746 ...
Biology Products: